Please login to the form below

Not currently logged in
Email:
Password:

Boehringer: Move towards trial transparency is "irreversible"

Pharma company plans to publish all scientific data

Move towards trial transparency is “irreversible” says Boehringer chair

Boehringer Ingelheim has become the latest company to say it will publish all scientific data from its clinical trials as the industry continues to feel pressure from open data campaigners.

Speaking at the Germany-based pharma company's annual conference, Boehringer's chair of the board of managing directors Professor Andreas Barner said the move towards transparency was “irreversible”, although there must be a standard format for trial publication that all companies follow.

“As a company that intensively and successfully conducts research, we will further intensify this exchange in the spirit of greater transparency by publishing all scientific data from all clinical studies for which the company is responsible,” said Prof Barner.

“In addition, we will in future make available to interested scientists all study data – up to the level of anonymised patient data – after the completion of the registration process and also when we have halted development.”

It was a bold move for the company, although it stopped short of joining GlaxoSmithKline in signing up to All Trials, a campaign group for open data that counts IQWIG and NICE among its supporters.

Nevertheless, Prof Barner said that transparency and availability of data was the “right direction” for the industry.

Questions remain on how the company will implement this promise, although Barner said that there should be a standard format for all companies to release data so that nobody is at a disadvantage.

Transparency has been a hot topic for pharma in recent months, stemming primarily from the Cochrane Collaboration's battle with Roche to release all data for flu drug Tamiflu after questions were raised about the medicine's efficacy.

Cochrane gained something of a victory earlier this month when Roche announced it would release data from all 74 Roche-sponsored trials involving Tamiflu to Cochrane over a period of several months.

However, the move was only given a cautious welcome from Cochrane, which raised concerns about the company's intention to edit the data to “ensure patient confidentiality and to protect legitimate commercial interests”.

Roche also faced criticism from AllTrials member group Sense About Science about the “years of persistence and publicity” that was needed to obtain the data.

26th April 2013

From: Research, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....